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A B S T R A C T
Age related neurodegenerative disorders (ARND) are presented as the most debilitating and challenging diseases
associated with the central nervous system. Despite the advent of active molecules with a positive role on
neurodegenerative mechanisms, many of the current therapeutic strategies remain ineﬀective in treating or
preventing ARND. Lipid nanocarriers have emerged as eﬃcient delivery systems with the capability to cross
biological barriers, especially the blood brain barrier (BBB). Also, when associated to natural compounds, lipid
nanocarriers have demonstrated to be an interesting alternative to ARND therapies with multiple beneﬁcial
eﬀects. This comprehensive review focus on state-of-the-art lipid based nanocarriers for the delivery of natural
compounds targeting neurodegeneration. A critical analysis of published reports will be also provided giving
indications to researchers about the most promising ARND nanotherapy strategies.
1. Introduction
Over the last decades, the incidence of diseases associated with
central nervous system (CNS) has greatly increased due to demographic
changes of population and growth of average life expectancy (Silva
et al., 2007). Within these diseases, age related neurodegenerative
disorders (ARND) are presented as the most debilitating and challen-
ging characterized by a gradual decline of neurological functions as
aging progresses. Of relevance, memory, cognition, motor coordination
and even emotional responses are disturbed (Lajtha et al., 2009).
Nowadays, ARND are the fourth leading cause of death in the in-
dustrialized world and aﬀect, approximately, 10 million people each
year (Olesen et al., 2012). According to data gathered in 2010, the
European annual cost associated with the treatment of brain disorders
was €798 billion (Olesen et al., 2012) and in United States was US$2.5
trillion and it is expected that these costs will duplicate by 2030
(Trautmann et al., 2016) which emphasizes the need to develop new
therapies. Due to complex molecular pathology, most of the current
therapeutic strategies remain ineﬀective for the treatment of ARND as
these are focused on a single molecular target and/or focused on
treating symptoms without halting neuronal cell loss. To date, there is
no curative or preventive therapy for ARND and the few drugs ap-
proved by FDA are focused in symptomatic relief (Modi et al., 2009).
Other therapeutic obstacle is the fact that bioactive neuroprotective
molecules present: small permeability and passage through biological
barriers and through the blood brain barrier (BBB); short half-life in the
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systemic circulation; and low bioavailability (Ballabh et al., 2004;
Pardridge, 2003; Spuch et al., 2012).
The success of new therapies will be related to their speciﬁcity, but
also to their multifunctional activities. In light of the overlapping
pathways of ARND, one suggested solution is to base eﬀective treat-
ments on agents that have several synergistic eﬀects, especially over a
duration that is related with the majority of neurological disorders
(Silva, 2006).
For all the mentioned reasons, classical therapies are not eﬀective,
and discovering new solutions to deliver bioactives is particularly im-
portant in the case of ARND. Accordingly, the EU Joint Programme on
Neurodegenerative Disease Research stresses the need to develop novel
systems for delivery and targeting of bioactives to the brain (EUJPND,
2012).
Despite the fact that the nanotechnologies are still at infancy stages
in clinical neuroscience application, there is a great interest in the po-
tential use of these novel therapeutic solutions (Spuch et al., 2012).
Among the various nanoscale delivery systems, lipid nanocarriers have
come out as central to ensuring that the delivery process is eﬃcient.
These nanocarriers (NC) provide a vehicle that is protected, which
shields the bioactives from destruction in an early stage, and also im-
proves their pharmacokinetic proﬁle (Nunes et al., 2015). Having in
mind the promising utility of lipid NC in the treatment of ARND and
owing to the fact that natural compounds have emerged as a promising
hope in the ﬁeld of drug discovery against these diseases (Devi, 2014),
the possibilities emerging from utilizing these strategies to treat CNS
disorders are exceptional. Hence, this review discusses and provides a
general summary of state-of-the-art of lipid based NC with conveyed
natural compounds in a therapeutic perspective targeting neurode-
generation. Additionally, it is presented a critical analysis of published
reports, discussing their eﬀectiveness, dissimilarities and developments,
as well as, their limitations and achievements giving indications to
predict how the lipid NC for natural compounds delivery will evolve
and provide better therapeutic solutions for ARND.
2. Etiology of age related neurodegenerative diseases: brief
overview
ARND are a diverse group of either arbitrary or hereditary disorders
that are characterized by a dysfunction of the nervous system that is
progressive (Lajtha et al., 2009; Zlokovic, 2008). ARND are multi-
factorial diseases that arise from slow and irreversible dysfunctions in
speciﬁc brain areas of the CNS which will, ultimately, delineate the
clinical consequences of these conditions. As previously mentioned,
aging is a major risk factor to develop neuropathologies although ge-
netics, environmental factors and endogenous dynamics also inﬂuence
its outset and progression (Lajtha et al., 2009; Zlokovic, 2008). How-
ever, the etiological and basic pathological mechanisms that explain
and cause these diseases are not yet fully understood (Jain, 2006). The
most incident conditions among ARND at a global scale are Alzheimer
disease (AD), Huntington disease (HD), spinal cord injury (SCI) amyo-
trophic lateral sclerosis (ALS), cerebral ischemia/reperfusion (CIR)
traumatic brain injury (TBI), Parkinson disease (PD), and multiple
sclerosis (MS), (Giacoppo et al., 2015). Although these neurodegen-
erative conditions exhibit some diﬀerences, particularly concerning
their etiological pathways and clinical manifestations, these diseases
exhibit overlapping features, such as: (i) an imbalanced proteostasis
(protein misfolding, aggregation and deposition), (ii) neuroinﬂamma-
tion and (iii) oxidative stress (Spuch et al., 2012). These common fea-
tures suggest the existence of converging pathways (Fig. 1) in a varying
extent of ARND (Durrenberger et al., 2015).
2.1. The amyloid β-peptide (Aβ peptide) deposition
The amyloid β-peptide (Aβ peptide) deposition in the hippocampal
and cerebral cortical regions is an etiological factor implicated on the
onset of several ARND, namely, AD. This deposition is associated with
the senile plaques (SP) and neuroﬁbrillary tangles (NFT) presence. SP
are neurotoxic extracellular Aβ peptide deposits build up between
nerve cells and derived from the amyloid precursor protein’s (APP)
secretase cleavage. At synapses, the little clumps of SP may bar sending
signals cell-to-cell. They can as well activate the cells of the immune
system, which can spark oﬀ inﬂammation and eliminate the cells that
are disabled (Tuppo and Arias, 2005). NFT are formed mainly by in-
tracellular aggregates of hyper phosphorylated microtubular tau pro-
teins, whereas SP are extracellular lesions that are complex where the
core containing Aβ is encircled by dystrophic neuritis, reactive micro-
glia, interleukins and ﬁbrillary astrocytes. (Richardson et al., 2002).
NFT destroy a vital cell transport system based on tau proteins. In AD,
tau collapses into twisted strands called tangles in a way such that
nutrients together with other supplies that are essential are unable to
move through the cells, leading to the cells death. Recent evidences
point also to the presence of intermediate aggregation products (Aβ
oligomers), in the extracellular or intracellular environment, that can
interact with lipid membranes promoting nonspeciﬁc ion leakage or
may form ion channel-like structures by transformation into annular
protoﬁbrils (Sciacca et al., 2012). Eventually, these anomalous channels
may compromise neuronal ionic homeostasis (Benilova et al., 2012;
Haass and Selkoe, 2007).
2.2. Oxidative stress
Oxidative stress is considered to be a key factor in the onset and
development of neurodegenerative diseases (Fischer and Maier, 2015).
Oxidative stress results from an unbalance between free radicals’ pro-
duction and scavenging. In healthy people, free radicals formation is a
usual physiological event critical for the function of CNS. The free ra-
dicals are made from metabolism by-products and include peroxynitrite
(ONOO−), hydrogen peroxide (H2O2), superoxide anion (%O2−), hy-
droxyl radical (HO%), nitroxyl radical (N2O2) and nitric oxide (NO%).
These free radicals combined are called the reactive oxygen species
(ROS) or reactive nitrogen species (RNS) (Chiueh et al., 2000). In a
pathological condition, there is an excess of ROS and RNS which da-
mages cellular lipids, proteins, and DNA, thereby, impairing their
normal function (Albarracin et al., 2012). The biochemical pathways
involved in oxidative stress are complicated, and this complications
give numerous therapeutic targets (Chen et al., 2012). Oxidative stress
has been showed to factor in several neurodegenerative diseases pro-
gression, like AD or PD. Toxicity of ROS and RNS also contributes to:
protein misfolding; subsequent cellular apoptosis; mitochondrial dys-
function; and glia cell activation (Fulda et al., 2010). Moreover, Aβ
peptide deposition might increase reactive oxygen species (ROS), which
are responsible for glutathione depletion and cell vulnerability to oxi-
dant attack (Pinnen et al., 2011).
2.3. Neuroinﬂammation
Neuroinﬂammation is especially relevant in chronic ARND such as
PD and AD and it is still looked at as a downstream consequence in
regards to the amyloid hypothesis, in which Aβ peptide accumulation in
the CNS induces microglia activation, triggering a pro-inﬂammatory
cascade, whose consequences are the release of substances that are
potentially neurotoxic that include cytokines, ROS, RNS, chemokines,
and diﬀerent proteolytic enzymes, resulting in neurodegeneration
(Eikelenboom et al., 2006; Griﬃn, 2006). It had been proposed that the
microglia and astrocytes activation by upregulation of complement
proteins, cytokines, and cyclooxygenase (COX), can result in tau
phosphorylation and neuroﬁbrillary tangles formation (NFT) (Zotova
et al., 2010). This provides an environment that is neuroinﬂammatory
and is believed to encourage neurodegeneration (Fischer and Maier,
2015). When astrocytes are activated for an extended period of time,
they can induce the release of extracellular matrix proteins, which can
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cause glial scar formation. This, on one hand, prevents the damaged
area from spreading, but limits tissue regeneration on the other hand
(Sofroniew, 2009).
3. Natural compounds as therapeutic alternatives to age related
neurodegenerative diseases
The multifactorial etiology of ARND suggests that drugs and other
active compounds should be able to target multiple receptors or ligands
so that the therapy can be eﬃcient (Devi, 2014; Ramassamy, 2006;
Silva, 2006; Zhang and Tang, 2006). However, the existing classical
drug therapies focus on single targets and altering the progression of
the disease and alleviating its symptoms without treating the neuronal
cell loss (Youdim and Buccafusco, 2005). Since a deﬁcit of acetylcholine
(ACh) is well known to exist in AD brain, cholinesterase (AChE) in-
hibitors are the current drugs that are approved to treatment AD.
However, these drugs cannot stop the neurodegeneration process but
are only able to aid in memory improvement in the cases of mild de-
mentia. Because the patient’s response to AChE inhibitors is dependent
on the presynaptic neurons integrity, these agents’ therapeutic eﬃ-
ciency decreases with AD severity. In addition, the side eﬀects of gastro-
intestinal are associated with their use (Sonkusare et al., 2005). Besides
AChE, N-methyl-D-aspartate receptors (NMDA) are the new targets of
the AD approved commercial drugs. NMDA are glutamate-gated cation
channels with high permeability for calcium (Ca2+) that are essential
in: CNS development; rhythms generation for locomotion and
breathing; and fundamental in learning, neuroplasticity, and memory
processes. Although the NMDA receptor physiological activity is critical
for ordinary neuronal function, too much of the glutamate receptors
activation of NMDA–types causes a Ca2+ excessive inﬂux via the ion
channel associated to the receptor, and this excitotoxicity is among the
central elements leading to neuronal injury and even resulting in death
in both chronic and acute neurologic disorders (Sonkusare et al., 2005).
NMDA-receptor antagonists are drugs used in classical AD and other
neurodegenerative diseases therapy since they block glutamate ex-
citotoxicity, however these drugs focus in one therapeutic target and it
is not completely known whether treatment beneﬁts continue after the
progression to moderate-to-severe diseases (Sonkusare et al., 2005).
Therefore, the quest for new therapeutic solutions for the treatment of
ARND continues and attention must be paid to drugs or other bioactives
that are nontoxic and possess several synergic eﬀects. In this context,
natural bioactive compounds are emerging as prophylactic and ther-
apeutic agents that execute neuroprotective eﬀects through a variety of
actions (Neves et al., 2012; Oliveira et al., 2016; Silva et al., 2004,
2008a; Silva et al., 2008b; Silva et al., 2007): (i) antioxidant action by
inactivation of ROS or RNS; regulation of anti-oxidant enzymes (e.g.
glutathione, superoxide dismutase and catalase) or protection of mi-
tochondrial function (mitoprotectors); (ii) anti-inﬂammatory action by
reduction the expression of pro-inﬂammatory factors (for example, the
tumor necrosis factor α (TNF-α) and IL-1β) that occur in neuroin-
ﬂammation and by inhibition of nuclear factor κB (NFκB); (iii) Aβ
peptide anti-aggregation and anti-ﬁbrillation eﬀects by providing a
boost to the immunological cells’ phagocytic properties to assist clear
Aβ senile plaques in AD, and Lewy bodies in PD or suppress neuro-
transmitter cleaving enzymes to increase neurotransmitter concentra-
tions in the neurons vicinity or even decrease tau abnormal phos-
phorylation; and (iv) general neuroprotective actions by having an
eﬀect on the neurons’ diﬀerentiation characteristics.
Fig. 1. Pathways involved in neurodegenera-
tion.
Secretase promotes the cleavage of amyloid
precursor protein (APP) which is determinant
in Amyloid β (Aβ) peptide aggregation in se-
nile plaques (SP) and neuroﬁbrillary tangles
(NFT). Aβ oligomers may also interact with
membranes forming abnormal ion channel-like
structures that compromise ionic homeostasis
of aﬀected neurons. Mechanisms involved in
Aβ-mediated neuronal death may include di-
rect neurotoxicity, neuroinﬂammation (due to
cytokine release, complement activation, COX
activity) and oxidative stress (by generation of
free reactive oxygen and nitrogen species (ROS
and NOS)). Activated microglia and astrocytes
may release neurotoxins, toxic inﬂammatory
mediators, and free radicals, inducing also
neuroinﬂammation and oxidative stress that
ultimately will be responsible by neurodegen-
eration.
T.B. Soares et al. Progress in Neurobiology xxx (xxxx) xxx–xxx
3
Table 1
Natural compounds and their beneﬁcial eﬀects in neurodegenerative condition.
Compound Chemical Family Natural Source Beneﬁcial Eﬀects Ref.
Baicalin and Baicalein Flavone Scutellaria baicalensis • Protects against neuronal cell damage induced by
Aβ accumulation, oxidative stress, and glutamate
induced toxicity
• Promising agent for prevention or therapy of CIR
injury, traumatic brain injury, AD, PD and
dementia
Mu et al. (2011) and Tu et al.
(2009)
Biapigenin Flavone Hypericum perforatum • Neuroprotective eﬀects against Aβ neurotoxicity
and excitotoxic insults
• Mitoprotective
Silva et al. (2004), Silva et al.
(2008a,b), Silva et al. (2009)
and Oliveira et al. (2016)
Chrysin Flavone Oroxylum indicum,
Passiﬂora caerulea,
Passiﬂora incarnata
• Exhibits anti-inﬂammatory activities and
suppresses immuno-inﬂammatory responses.
• Mitoprotective• Neuroprotective via a reduction of nitric oxide,
TNF-α, IL-1β, IL-6 and inhibition of NFκB and
COX-2
• Attenuates oxidative damages and cognitive
dysfunction associated with Aβ
Zeinali et al. (2017)
Chrysophanol Anthraquinone Rheum palmatum • Neuroprotective eﬀects against CIR injury• Inhibition of oxidative stress or neuronal
apoptosis-related pathways
Lin et al. (2015)
Curcumin Diarylheptanoid
(curcuminoid)
Curcuma genus • Inhibition of NFκB• Decreases Aβ-ROS related inﬂammation• Inhibits Aβ induced cell death• Protects neurons from glutamate induced toxicity• Prevents neuronal loss promoting adult
neurogenesis
• Preserves pre and post synaptic proteins.
Ray and Lahiri (2009)
Epigallocatechin gallate (EGCG) Catechin Camellia sinensis • Mitoprotective• Inhibits Aβ ﬁbrillation and redirects Aβ
aggregation into unstructured, oﬀ-pathway
oligomers
• Neuroprotective eﬀect against cerebral ischemia-
induced oxidative stress
Walker et al. (2015)
Gallic acid Phenolic acid Abundantly present in
fruits, tea and nuts
• Neuroprotective against hypoxia/ reoxygenation-
induced mitochondrial dysfunctions
• Ameliorated cognitive deﬁcits and cerebral
oxidative stress and exerts beneﬁcial eﬀects on
behavioral impairments after brain CIR
Daglia et al. (2014)
Ligustrazine phosphate Alkaloid Ligusticum chuanxiong
Hort
• Treatment of CIR injury• Anti-apoptotic and anti-inﬂammatory activity
Shi et al. (2012)
Luteolin Flavone Salvia tomentosa • Lowered the intracellular ROS level and increased
the neuron survival
• Prevents Aβ-induced apoptotic neuronal death
Xu et al. (2014)
Piperine Alkaloid Piperis nigri • Anti-inﬂammatory, anti-depressant, antioxidant
and cytoprotective eﬀects.
• Acts on oxidative cascade, cholinergic system and
decreases the Aβ aggregates and NFT in brain
tissues
Yang et al. (2015)
Quercetin Flavonol Diﬀerent natural sources:
Fruits, red wine and Tea
• Increases the neuronal resistance against
excitotoxicity by modulation of cell death
mechanisms
• Free radical quenching, iron chelating and anti-
inﬂammatory properties
• Strongly inhibits Aβ ﬁbrillation
Sabogal-Guaqueta et al.,
(2015)
Resveratrol Stilbene Vitis vinifera and diﬀerent
natural sources
• Antioxidant eﬀects• Neuroprotective eﬀects against Aβ neurotoxicity
and reduced Aβ triggered neuroinﬂammation
Li et al. (2012)
Rosmarinic acid Phenolic Acid
derivative
Species of Boraginaceae
and subfamily
Nepetoideae of Lamiaceae
• Potent antioxidant activity associated to its
radical scavenging activity
• Anti-inﬂammatory activity• Strong anti-Aβ aggregation eﬀects
Kim et al. (2015)
(continued on next page)
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A summary of the most reported natural compounds with neuro-
protection eﬀects is presented in Table 1.
4. Challenges in the administration of natural compounds for
neuroprotection
4.1. Low bioavailability and poor pharmacokinetic proﬁles
The brain is very vulnerable to oxidative stress and recently,
bioactives with anti-inﬂammatory and antioxidant eﬀects have gained
relevance on the prevention of the damages caused by free radicals and
also on the treatment of ARND (Albarracin et al., 2012; Aquilano et al.,
2008). Many of bioactive antioxidant and anti-inﬂammatory agents are
provided by food and several studies show that diets rich on these
compounds play an important role on ARND prevention, however their
beneﬁcial eﬀect is greatly aﬀected by their low bioavailability and poor
pharmacokinetic proﬁle (Albarracin et al., 2012; Manach, 2004).
For decades, the administration of drugs into a person has been
accomplished via various routes: oral, parenteral, topical, and inhala-
tional, among others. Of all the routes, oral administration is the major
conventional and well accepted method for drug delivery. However,
oral administration has several problems such as variable absorption,
fast metabolism, and poor bioavailability mostly because of pH varia-
tion conditions and the digestion of the administrated actives due to the
presence of proteolytic enzymes in the gastrointestinal tract (Lúcio
et al., 2010). To be eﬃciently absorbed from the digestive tract, an
element has to cross the enterocytes plasma membrane that covers the
gut lumen. Most of the compounds cross this membrane through pas-
sive diﬀusion via the lipid bilayer, but for that being possible it is es-
sential that the bioactives possess the required balance of lipophilicity/
hydrophilicity (Lúcio et al., 2010). After passing the absorption obstacle
and reaching circulation, the bioactive redistributes throughout the
body. However, the redistribution can be hindered by a number of
obstacles. The hydrophobic actives are often extensively bound to
plasma proteins to be able to be transported in blood. As a consequence
the bioactives may be accumulated in adipocytes or rapidly change in
the liver into hydrophilic metabolites and be removed through urine or
excreted into the bile (Lúcio et al., 2010).
In summary, due to the poor solubility and permeability, instability
or even the biotransformation that happens before and after bioactives
enter systemic circulation it is diﬃcult for these compounds to reach
the brain (Ratnam et al., 2006). Ultimately, even if a bioactive for
ARND treatment is able to be absorbed and distributed in the body long
enough to reach the brain, it still has to overcome other blood–tissue
barriers like the blood-brain barrier (BBB) (Lúcio et al., 2010). Hence,
one of the challenges nowadays is to create NC that are able to deliver
bioactives directly to the brain overcoming the biological barriers found
by these compounds (Alam et al., 2010).
4.2. Overcoming blood brain barrier – a major challenge
The treatment of neurological diseases is not an easy task, especially
due to the brain physical barriers like the BBB. It is the crucial barrier
when we are dealing with the transport of compounds from blood into
Table 1 (continued)
Compound Chemical Family Natural Source Beneﬁcial Eﬀects Ref.
Safranal Monocyclic
Monoterpene
Crocus sativus • Antioxidant eﬀects: inhibition of lipid
peroxidation and oxidative DNA damage
• Neuroprotective eﬀects: reduces neural cells
apoptosis; reduces metabolic and behavioral signs
of acute stress; attenuates edema in the spinal
cord and inhibits GABAergic in the cortex and/or
hippocampus
• Downregulates inﬂammatory reactions
Zhang et al. (2015)
Salvianolic acid B Phenolic Acid
derivative
Salvia miltiorrhiza (Red
sage or chinese sage)
• Strong antioxidant and free radicals scavenger
activity
• Inhibits Aβ -induced neuronal toxicity• Neuroprotective via a reduction of nitric oxide,
TNF-α, ROS, and IL-1β levels
Zhang et al. (2016)
Sasanqua saponin Triterpenoid saponin Seeds of Camellia oleifera • Anti-inﬂammatory, antifungal and anti-
hyperlipidemia eﬀects.
• Antioxidant, analgesic and other pharmacological
activities
Ye et al., (2014)
Schisantherin A Lignan Schisandraceae family • Antioxidant and anti-inﬂammatory properties• Neuroprotective eﬀects against neuronal cell
death from toxicity induced by glutamate, Aβ
peptide and hydrogen peroxide
Sa et al., (2015a,b)
Sesamol Lignan Sesame seed oil from
Sesamum species
• Powerful antioxidant and inhibits UV- and Fe3+/
ascorbate-induced lipid peroxidation
• Neuroprotective, anti-inﬂammatory and anti-
aging properties
Narasimhan et al. (2011)
Thymoquinone Monocyclic
Monoterpene
Nigella sativa • Antioxidant and anti-inﬂammatory eﬀects• Potent free radical and superoxide radical
scavenger
• Eﬀect on aging and memory impairment• Attenuates Aβ25-35-induced toxicity and protects
against neurotoxin Aβ1-40
Gholamnezhad et al. (2016)
Aβ: Amyloid β-peptide ; AD: Alzheimer disease; CIR: Cerebral Ischemia Reperfusion; COX-2: Cyclooxygenase-2; EGCG: Epigallocatechin gallate; GABA: γ-
Aminobutyric acid NFκB: Nuclear factor κB; NFT: Neuroﬁbrillary tangles; PD: Parkinson disease; ROS: Reactive Oxygen Species; TNF-α: Tumor necrosis factor α;
UV: Ultraviolet radiation.
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brain (Fig. 2), providing the protection of the CNS (Chen and Liu, 2012;
Gaillard et al., 2012).
BBB is made up of endothelial cells without fenestrations char-
acterized by the presence of tight junctions, which form a continuous
cellular membrane that restricts the transport of molecules. This dif-
fusion barrier keeps the CNS homeostasis by transporting the required
nutrients to the brain for its normal functions (Cardoso et al., 2010; Lun
et al., 2012). BBB is also composed by pericytes and astrocytes. The
pericytes are essential for the structural support. These cells are also
associated with transport across the BBB and in the vessels’ diﬀer-
entiation, as well as in formation of endothelial tight junctions (Ballabh
et al., 2004; Cardoso et al., 2010). Astrocytes are glial cells and are
important for the normal neuronal function (Cardoso et al., 2010).
BBB is not only a protective barrier, but also a transport barrier that
regulates and provides several routes for the transport of molecules to
the brain. Substance diﬀusion into the brain can be classiﬁed into
paracellular (transport of ions and solutes between adjacent cells
through the tight junctions and according to their concentration) and
transcellular (transport of solutes through the cells) (Cardoso et al.,
2010). When it comes to the transcellular pathway it involves diﬀerent
mechanisms such as: transport made by carrier proteins (carrier-
mediated transport; CMT); speciﬁc receptor-mediated mechanisms
(receptor mediated transcytosis; RMT) or vesicular mechanisms
(adsorptive mediated transcytosis, AMT). CMT allows little mole-
cules (like glucose or amino acids) binding to speciﬁc membrane pro-
tein carriers (Alam et al., 2010; Chen and Liu, 2012). RMT mechanism
consists in the transport of macromolecules such as transferrin, insulin,
or leptin, and it is mediated by speciﬁc receptors present on the en-
dothelial cells (Chen and Liu, 2012; Pardridge, 2003). AMT mechanism
of transport through BBB is initiated due to an electrostatic interaction
that occurs between a plasma membrane that is negatively charged and
a substance that is positively charged (Chen and Liu, 2012).
Although there are several routes to cross BBB, the molecules that
can pass it by passive diﬀusion must possess very speciﬁc characteristics
like small size and endothelial permeability, which are very hard to
fulﬁl. Therefore, it was already proved that 98% of neurotherapeutic
molecules cannot pass across the BBB (Zlokovic, 2008). Circumventing
BBB could thus be achieved through the administration of nanodelivery
systems that can target and control the release of diﬀerent bioactive
agents that are used to treat ARND.
5. Nanocarriers as an emerging platform for drug delivery to brain
There are signiﬁcant challenges when treating CNS disorders and a
possible solution to these diﬃculties is the use of Nanotechnology. The
possibility of using NC with advantageous characteristics, like high
biological and chemical stability, possibility of integrating both hy-
drophobic and hydrophilic drugs, biologicals (enzymes, peptides or
nucleic acids) or other bioactive compounds, and the possibility of
being administered using diﬀerent ways (including inhalational, oral,
and parenteral) makes NC attractive for medical applications (Martin-
Banderas et al., 2011). NC systems for the delivery of bioactive com-
pounds to treat ARND possess additional features over classical thera-
pies: (i) the possibility to encapsulate diﬀerent payloads with synergic
eﬀects that are eﬃcient at multiple etiological targets (Silva, 2006;
Spuch et al., 2012); (ii) the power to attain speciﬁc biodistribution
proﬁles that were not possible before microscale delivery systems or
with purely molecular (Etheridge et al., 2013) and the possibility to
functionalize NC surface with targeting ligands that make use of BBB
transport routes for eﬀective delivery of bioactives to the brain (Alam
et al., 2010; Tosi et al., 2016).
NC design strategies of stealth, targeting and triggering have been
developed for their numerous advantages: sustained and local delivery
of bioactives to provide a higher therapeutic eﬀect; reduce toxicity
while able to maintain the therapeutic eﬀects; biocompatibility and
greater safety; reduction in high-dose-associated side eﬀects and ad-
justable/controlled bioactive delivery rate that increase the duration of
eﬀect (Jong and Borm, 2008; Kim et al., 2009; Kumar et al., 2014).
These strategies (Fig. 3) are particularly important for the rational de-
sign of NC aiming the delivery of bioactive compounds to treat ARND.
5.1. Stealth strategies
When in blood circulation, the immune system easily recognizes NC
and clear them with phagocytes thereby reducing their chances to reach
target tissues. Stealth strategies consist on coating NC surface with
hydrophilic chains (e.g. polyethylene glycol, PEG) to enhance the sta-
bility of NC against aggregation. Such modiﬁcation (named as
“PEGylation”) reduces opsonisation of NC in plasma and decreases its
recognition and removal by the mononuclear phagocytes (dendritic
cells, monocytes, and macrophages) (Kabanov and Gendelman, 2007).
Fig. 2. Transport pathways across Blood Brain
Barrier (BBB).
The main routes for molecular traﬃc across the
BBB are shown as well as the type of solutes
that use each pathway. Nanocarriers (NC)
preferential pathways are (i) receptor medi-
ated transcytosis (RMT) when the NC surface is
functionalized with ligands recognized BBB
receptors and (iii) adsorptive-mediated trans-
cytosis (AMT) when the NC surface is posi-
tively charged.
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5.2. Targeting strategies
There are two types of targeting strategies that maybe used when
designing NC for delivery of therapeutics: passive targeting and active
targeting strategies.
5.2.1. Passive targeting
Passive targeting strategies are the physical properties of NC (e.g.
size and surface charge) that we can control to enhance their delivery to
a speciﬁc target tissue. The range of 2–200 nm is the NC size that is
desirable for systemic administration due to therapeutic reasons (Jo
et al., 2015). Nevertheless, NC smaller than 5 nm are at the risk of renal
excretion: even if they escape renal excretion, they suﬀer rapid clear-
ance from target tissues. Therefore sizes superior to 5 nm are preferable
to reach higher circulation times (Jo et al., 2015). In the development
of nanotherapeutics against CNS diseases, NC of 20–100 nm, have
proved to be big enough to avoid renal glomerular ﬁltration and small
enough to pass through BBB (Jo et al., 2015). Larger NC will not pas-
sively overcome BBB and will require active targeting strategies (de-
scribed below). NC upper size limit is thought to be around 200 nm, as
NC larger than this size are scavenged by reticuloendothelial systems
(RES), chieﬂy the liver’s Kupﬀer cells and the spleen’s macrophages.
Bigger particles that are larger than 2 μm are also caught by the pul-
monary capillary vessels (Jo et al., 2015).
In addition, NC surface charge modulates biodistribution, interac-
tion with biological environments, and cellular uptake. In general, NC
that are positively charged are acknowledged as internalized more ea-
sily than NC that are negatively and neutral charged (Jo et al., 2015). In
the case of BBB targeting, a positive surface charge is more advanta-
geous as it will favor NC uptake by AMT transport (Fig. 3).
5.2.2. Active targeting
Active targeting strategies consist on NC surface functionalization
with ligands (for example, monoclonal antibodies, sugar moieties,
peptide fragments, or other ligands that partake in recognizing re-
ceptors) that bind to signal receptors at the target tissues. These stra-
tegies favor NC targeted delivery to given areas, while avoiding accu-
mulating bioactives in nontargeted tissues.
BBB is impermeable for most of the NC, therefore targeting strate-
gies are essential when developing brain delivery systems. Moreover,
targeting moieties bounded to the NC surface (Fig. 3) will facilitate the
speciﬁc delivery of therapy to brain while avoiding toxic oﬀ-target ef-
fects resultant from NC accumulation in healthy tissues. Among the
transport mechanisms across BBB, RMT and AMT are the ones with
most potential for NC brain transcytotic uptake (Fig. 2). Table 2 sum-
marizes the reported strategies for targeting NCs to BBB using these two
transport mechanisms.
RMT transport is the most common pathway for NC uptake into
brain and consists of: (i) interaction of the NC surface ligands with
speciﬁc receptors that are expressed on BBB (targeting ligand strategies
mentioned on Table 2); (ii) formation of endocytotic-vesicles envel-
oping NC; (iii) transcytosis across the BBB; and (iv) exocytosis of NC in
CNS parenchyma.
Lipid NC have additional advantages over other NC (polymeric or
inorganic, for instance) regarding their capacity to overcome BBB, as
lipid nanoparticles are thought to mimic LDL particles and subse-
quently, the LDL receptor transports them, even when they are not
decorated at the surface with targeting ligands (Alam et al., 2010).
AMT transport depends on the electrostatic interaction of ligand of
the NC surface that is positively charged with the luminal surface of
endothelial cells that have negative charges. For a more extensive
reading on BBB targeting strategies, please refer to reviews on the
subject (Alam et al., 2010; Tosi et al., 2016).
Other strategies of targeting and/or increasing the permeability of
the BBB vascular endothelium consist on NC surface functionalization
(e.g. with PS80 and SDS) or incorporation of adjuvants (e.g. DMSO,
Fig. 3. Nanocarriers design strategies.
Targeting strategies for BBB include nano-
carriers surface functionalization with: ligands
(e.g: insulin and transferrin) that target re-
ceptors of the BBB; monoclonal antibodies
(mAb) that target Aβ peptide receptors or other
receptors at BBB and cationic carriers that
target negatively charged BBB endothelium.
Triggering strategies include lipids sensitive to
several stimuli (pH, temperature and reactive
oxygen species, ROS). Stealth strategies are
normally surface functionalization with poly
(ethylene) glycol (PEG).
Table 2
Targeting strategies for transport of NC across BBB.
BBB Transport system Receptors/Target Targeting ligand strategy
Receptor mediated
transcytosis
(RMT)
InsR Ins; InsR mAb
IGF1R, IGF2R IGF
TfR Tf; TfR mAb
LepR Lep
SR-B1 or AceLDLR LDL, LN
LDLR and LRP Apolipoproteins PS80
GpR Man
Aβ peptide Aβ mAb
Adsortive mediated
transcytosis
(AMT)
Negative
glycoprotein on
endothelial capillary
Cationic ligands (CPP like TAT
derived peptides; cationic
proteins; cationic lipids)
Adjuvant mediated
BBB disruption
BBB cellular
membrane
PS80, ethanol, DMSO, SDS
AceLDLR: Acetylated LDL receptor; Aβ peptide: Amyloid β-peptide; CPP: Cell
penetrating peptides; DMSO: Dimethilsulfoxide; GpR: Glucoprotein receptor;
IGF: Insulin-like growth factor; IGF1R and IGF2R: Insulin-like growth factor
receptors; Ins: Insulin; InsR: Insulin receptor; LDL: Low-density lipoprotein;
LDLR: Low-density lipoprotein receptor; Lep: Leptin; LepR: Leptin receptor;
LN: Lipid nanoparticle; LRP: Low-density lipoprotein receptor related protein;
mAb: Monoclonal Antibody; Man: Mannose; PS80: Polysorbate or Tween 80;
SDS: Sodium lauril sulfate; SR-B1: Scavenger receptor type B1; TAT: CPP de-
rived from the HIV trans-activator of transcription; Tf: Transferrin; TfR:
Transferrin receptor.
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ethanol) in the NC composition (Table 2).
5.3. Triggering strategies
Triggering strategies (Fig. 3) consist on using NC containing stimuli-
responsive moiety to trigger the release of bioactives (e.g. pH, tem-
perature or enzymatic triggering). Bioactives’ release triggered by a pH
decrease has been used to improve delivery of encapsulated therapies to
the more acidic tissues (e.g. inﬂamed or cancer tissues) and thus can be
used as a strategy for ARND with associated neuroinﬂammation. Fur-
thermore pH-responsive systems can be applied for external and in-
ternal (endosomes) cellular release. High levels of ROS produced in
ARND can also be used as triggering strategies on NC that are labile
upon oxidative conditions inducing their cargo release. For a more
complete description over stimuli-responsive triggering strategies,
please refer to a review on the subject (Mura et al., 2013).
6. Lipid nanocarriers for the treatment of age related diseases
Lipid-based NC are frequently chosen over other NC as they mimic
in many ways the natural lipid environment found on biomembranes
and often present lower toxicity when applied in vivo (Pujara, 2012).
Furthermore, lipid based NC are able to reach the brain using physio-
logical transport mechanisms, like the LDL receptor pathway (Alam
et al., 2010).
Examples of lipid based NC used for ARND treatments are: lipo-
somes; micelles; nanoemulsions such as self-nanoemulsifying drug de-
livery systems (SNEDDS) and self-double-emulsifying drug delivery
system (SDEDDS); lipid NC with solid matrix (SLN and NLC) and
ethosomes. These diﬀerent types of lipid based NC are represented in
Fig. 4 and will be brieﬂy described.
6.1. Liposomes
Liposomes are formed by amphiphiles (e.g. phospholipids) that,
once dispersed in an aqueous media, self-assemble as vesicles (Lúcio
et al., 2010). This vesicles are composed by lipid bilayers, where the
hydrophobic part of the amphiphiles (hydrophobic fatty acid chains)
will be oriented away from the aqueous polar phase, whereas the mo-
lecules’ polar portions (head group region) are exposed to the aqueous
solvent that exists in the vesicle core and also surrounding the vesicle
(Lúcio et al., 2010) (Fig. 4).
The use of liposomes as NC for drug delivery, has been focused on
the production of three types of liposomes: multilamellar vesicles
(MLV), composed by several lipid bilayers approximately concentric;
large unilamellar vesicles (LUV), that have a size range comprised be-
tween 100 and 500 nm; and small unilamellar vesicles (SUVs) smaller
than 100 nm (Allen and Cullis, 2013). Nonetheless, the properties of
liposomes are extremely adaptable, changing with size, preparation
method and lipid composition, which determines the strength and
charge of the liposomal surface (Allen and Cullis, 2013). The tunable
nature of liposomes increase its potential to achieve high encapsulation
of active compounds.
There are numerous liposomal preparation methods, including: (i)
lipid ﬁlm hydration method followed by mechanical approaches such as
homogenization techniques (e.g sonication, microﬂuidization, extru-
sion); (ii) approaches based in the replacement of organic solvents by
aqueous solutions (e.g. ethanol injection); (iii) reverse phase evapora-
tion techniques and (iv) techniques based in detergent removal. The
selection of the applied method is intrinsically connected with the
Fig. 4. Types of lipid based nanocarriers.
SLN: Solid lipid nanoparticles; NLC: Nanostructured lipid carriers; SNEDDS: Self-nanoemulsion drug delivery systems; SDEDDS: Self-double emulsion drug delivery
systems; O: oil phase; W: water phase.
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following parameters: (i) properties of the constituent lipids and of the
encapsulated compounds; (ii) nature of the medium in which lipid ve-
sicles will be dispersed; and (iii) therapeutical application. Along with
these parameters, it is perceptible that most of the liposomal prepara-
tion methods are inadequate for large scale production and that the
ethanol injection and the lipid ﬁlm hydration method followed by ex-
trusion are the most frequently used (Allen and Cullis, 2013; Lúcio
et al., 2010).
6.2. Lipid nanocarriers with solid matrix: solid lipid nanoparticles (SLN)
and nanostructured lipid carriers (NLC)
Over time, lipid NC with solid matrix have increased its popularity
regarding the transport of low-aqueous soluble drugs (Pardeike et al.,
2009; Üner and Yener, 2007). In comparison with liposomes, these NC
present advantages like the higher protection of incorporated active
compounds and an easy scale up potential (Üner and Yener, 2007).
These NC can be prepared by diﬀerent methods described in the
literature: ultrasonication, microemulsion, emulsiﬁcation-solvent eva-
poration, phase inversion, solvent displacement, emulsifalsoication-
solvent diﬀusion, and the most used owing to its scale up potential -
high pressure homogenization technique (Pardeike et al., 2009; Üner
and Yener, 2007). However, all of these methods are based on solid
lipid or lipid blends (mixture of solid and liquid lipid) fusion. Brieﬂy,
the lipid phase is melted being posteriorly dispersed through high-speed
agitation in an aqueous solution of equivalent temperature containing a
tensioactive or a stabilizer. Afterwards, the obtained pre-emulsion is
homogenized, recurring to a high-pressure homogenizer, achieving an
oil/water nanoemulsion. At last, emulsion droplets crystalize forming
lipid NC with a solid matrix (if all lipid components are solid) also
known as Solid Lipid Nanoparticles (SLN) or forming NC with a
matrix containing solid and liquid lipids designated as Nanostructured
Lipid Carriers (NLC) (Pardeike et al., 2009; Üner and Yener, 2007).
Thus, these NC present a hydrophobic matrix covered by a tensioactive
layer that favors their dispersion in water (Fig. 4). The active compound
is dissolved during the fusion step and before the high-shearing step
either in the ﬂuid lipid phase or in the aqueous phase, according to its
chemical nature. Depending on the position and distribution of the
active compound it is possible to distinguish three incorporation models
both at SLN or NLC: the model of homogenous matrix that presents the
actives distributed in the lipid matrix; the model of enriched shell
where the therapeutic agent is at the surface of the NC; and, the model
of enriched nucleus where actives possess a nuclear location and are
surrounded by lipids with a protective purpose (Pardeike et al., 2009;
Üner and Yener, 2007).
Despite their similarities in preparation and active compounds in-
corporation, there are important diﬀerences between SLN and NLC. SLN
are predominantly composed by saturated monoacid triglycerides and
hard fats, which are solid at body and room temperature, and that
enables mobility reduction of the incorporated active compounds,
preventing their release from the carrier (Pardeike et al., 2009; Üner
and Yener, 2007). Contrastingly to highly ordered SLN, NLC possess a
less ordered solid matrix which demonstrates a superior charge capacity
of active compounds, minimizing their undesirable expulsion during
storage (Pardeike et al., 2009). NLC can be classiﬁed as: imperfect
crystalline structure NLC, obtained through a mixture of solid lipids
with low quantities of liquid lipid; amorphous NLC, composed by a
mixture of solid lipids with lipids that are unable to recrystallize after
homogenization; and, ﬁnally, multiple NLC, formed by a mixture of full
or medium chain solid lipids (Üner and Yener, 2007).
6.3. Ethosomes
Although classic liposomes are outstanding candidates for drug
delivery, their ability to inﬁltrate the skin is still reduced, decreasing its
potential for transdermal drug delivery. In this way, ethosomes were
developed as lipid vesicular systems composed by: phospholipids;
ethanol (known as an eﬃcient permeability enhancer) in high quan-
tities (20–45%), and water. This ethosomal system is known to improve
transdermal drug delivery, both in vitro and in vivo. The mode of action
of ethosomes is based on the interaction of ethanol with lipid molecules
that are located in the polar head group region, which increases the
ﬂuidity of the lipid membrane. The ethanol intercalation may furnish
the vesicles with soft ﬂexible properties that makes it possible for pe-
netration of deeper skin layers. The same rationale can be applied to
brain delivery as ethosomes characteristics might be useful to promote
BBB permeabilization and delivery of bioactives to the brain (Table 2).
Considering their production, these vesicular systems are prepared
in a closed recipient through the dissolution of the drug and lipids in
ethanol, with the slowly addition and ﬁne ﬂow of the aqueous com-
ponent at a constant rate and under constant mixing.
In comparison with liposomes, ethosomes similarly hold the ad-
vantage of presenting small dimensions due to the negative net charge
in vesicle surface induced by the presence of ethanol. Furthermore,
these novel phospholipid vesicular carriers seem to be capable of car-
rying in an eﬃcient manner compounds of diﬀerent lipophilicities
(Godin and Touitou, 2003).
6.4. Micelles
Micelles are self-assembly aggregates of surface-active agents (sur-
factants) that occur above a concentration that is well-deﬁned and is
called the critical micelle concentration (CMC). The structure of the
surfactants’ hydrophobic tails and head groups included in micelles
composition controls their packing parameter (PP), thereby controlling
the physical properties of the micelles, viz. the CMC and their ag-
gregation number. In aqueous bulk media, inverted conical shaped
surfactants (PP < 1) aggregate in a single lipid layer rather than bi-
layers: the surfactants’ hydrophobic part that forms the micelle is or-
iented in the cluster and located away from the aqueous polar phase,
whereas the molecule polar parts (head groups) are exposed to the
solvent (Fig. 4). In a reduced aqueous content, conical shaped surfac-
tants (PP > 1) can aggregate in an inverted structure (inverted mi-
celles) (Fig. 4). In both cases, micelles and inverted micelles possess
polar and apolar regions and can be used as simple delivery systems
able to carry hydrophobic and hydrophilic bioactive compounds
(Torchilin, 2006).
6.5. Nanoemulsions
Nanoemulsions are colloidal dispersions that can be produced from
oil, water, and surfactants, and originate small emulsion droplets with
sizes of 10–100 nm. Normally, nanoemulsions can be assorted as bi-
continuous, water-in-oil (W/O) and oil-in-water (O/W). Also, the pro-
cess used to prepare nanoemulsions as well as their composition and the
environmental conditions are responsible to deﬁne their structure,
creating a variety of diﬀerent systems (Date et al., 2010; McClements,
2012).
Nanoemulsions are widely used as delivery systems due to their
advantages: i) ability to solubilize hydrophilic and hydrophobic agents;
ii) improved stability of agents; iii) greater esthetic appeal and skin feel
when administrated as transdermal formulations; iv) improved dermal
and mucosal transport; v) improved oral bioavailability; vi) ﬂow
properties ranging from liquid to highly solid; vii) optical properties
ﬂuctuating from opaque to nearly transparent and viii) easy manu-
facture and scale up (Date et al., 2010; McClements, 2012). Despite the
numerous advantages of nanoemulsions, these delivery systems are
thermodynamically unstable requiring a speciﬁc design to reach a sa-
tisfactory kinetic stability (Date et al., 2010; McClements, 2012).
In respect to the methods used for nanoemulsions fabrication, they
can be separated into low-energy emulsiﬁcation methods or high-en-
ergy emulsiﬁcation methods. The ﬁrst, low-energy emulsiﬁcation
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Table 3
Lipid nanocarriers containing natural compounds (Barras et al., 2009; Campos et al., 2014; Neves et al., 2013; Ramachandran and Thangarajan, 2016; Vanaja et al.,
2013; Wang et al., 2011).
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Table 3 (continued)
AD: Alzheimer disease; β-CD: 2-hydroxypropyl-β-cyclodextrin; ApoE: Apolipoprotein E; BCEC cells: brain capillary endothelial cells; CA: Citric Acid; CAPMUL®MCM:
mono-diglyceride of medium chain fatty acids (mainly caprylic and capric); Caco-2 cells: heterogeneous human epithelial colorectal adenocarcinoma cells; CAPTEX®
500: glyceryl triacetate or triacetin; CHOL: Cholesterol; CHOL-O: Cholesteryl oleate; CHS: Chitosan; CO: Castor oil; COMPRITOL®888 ATO: blend of diﬀerent esters of
behenic acid with glycerol or glyceryl behenate; CREMOPHOR® EL: KOLLIPHOR® EL or Macrogolglycerol ricinoleate or PEG-35 castor oil or Polyoxyl 35 hydro-
genated castor; CREMOPHOR® RH40: KOLLIPHOR® RH40 or Macrogolglycerol hydroxystearate or PEG-40 castor oil, Polyoxyl 40 hydrogenated castor oil; DBC cells:
Dissociated brain cells; DCP: Dicetylphosphate or dihexadecyl phosphate; DOPE-PEG-N3: 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine grafted with PEG azide;
DPPC: 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine or Dipalmitoyl phosphatidylcholine or 1,2-dipalmitoyl-sn-glycero-3-phosphocholine or 1,2-Dipalmitoyl-3-
sn-phosphatidylcholine or 1,2-Dipalmitoyl-L-lecithin; DPPG: 1,2-dihexadecanoyl-sn-glycero-3-phospho-(1′-rac-glycerol) or 1,2-dipalmitoyl-sn-glycero-3-phospho-(1′-
rac-glycerol); DPS-CUR: conjugate of phospholipid (1,2- dipalmitoyl-3-(2-(1,7-bis(4-hydroxy-3-methoxyphenyl)-3,5- dioxohept-6-enylthio)ethyl phospho)-sn-gly-
cerol) and curcumin; DSPE-PEG2000: Conjugate of 1,2- distearoyl sn-glycero-3-phosphoethanolamine and polyethylene glycol (2000) monostearate DPS-PEG2000-
CUR: Conjugated of DSPE-PEG2000 and curcumin; DSPE-PEG2000 maleimide: 1,2- distearoyl sn-glycero-3-phosphoethanolamine-N-(maleimide(poly-
ethylenoglycol)-2000; DSPC: 1,2-distearoyl-sn-glycero-3-phosphocholine or 1,2-dioctadecanoyl-sn-glycero-3-phosphocholine; EGCG: Epigallocatechin gallate; EPC:
egg phosphatidylcholine; EPSO: evening primrose seed oil; G62: GELUCIRE 62/5® i.e. family of lipid-based excipients comprising mono-, di-, and triglycerides and
mono- and di-fatty acid esters of PEG, in this case 62 is referring to the nominal melting point of the base and 5 is the hydrophilic-lipophilic balance; GMS: Glycerol
monostearate; hAPPsw SH-SY5Y cells: SH-SY5Y cells stably overexpressing the human APP gene (hAPP) bearing the Swedish mutation (causing familial Alzheimer
disease); HBLEC cells: Human brain-like endothelial cells obtained by culturing endothelial cells derived from hematopoietic stem cells isolated from umbilical cord
blood; hCMEC/D3 cells: Immortalized human brain capillary endothelial cells; HEK cells: cells from Human Embryonic Kidney; HSPC: Hydrogenated soybean
phosphatidylcholine or L-α-phosphatidylcholine, hydrogenated (Soy) or PHOSPHOLIPON® 90 H; HUVEC cells: human umbilical vein endothelial cells; i.c.v ad-
ministration: intracerebroventricular administration i.p. administration: intraperitonal administration; i.v. administration: intravenous administration; LABRAFAC®:
Caprylic/Capric triglyceride; LABRAFAC®PG: Propylene glycol dicaprylocaprate; LABRASOL®: mono-, di- and triglycerides and mainly PEG-8 (MW 400) mono- and
diesters of caprylic (C8) and capric (C10) acids also designated as Caprylocaproyl Polyoxyl-8 glycerides or PEG-8 caprylic/capric glycerides; LB-509: α-synuclein
antibody; Lf: Lactoferrin; mAb: monoclonal antibody; MAN: p-aminophenyl-α-ᴅ-mannoside; MIGLYOL®812: caprylic/capric triglycerides; MYRJ®52:
Polyoxyethylene (40) stearate; n.i.: not indicated; n.t.: not tested; OX26: Transferrin antibody; P188: Poloxamer 188 or PLURONIC F68® or KOLLIPHOR P188® or
LUTROL F68®; PC: 1,2-diacyl-sn-glycero-3-phosphocholine or Phosphatidylcholine or Diacylphosphatidylcholine or lecithin or EPIKURON® 200 or PHOSPHOLIPON®
90 G; PA: Palitic acid; PC12 cells: cells derived from a pheochromocytoma of the rat adrenal medulla; PE: 1,2-diacyl-sn-glycero-3-phosphoethanolamine or phos-
phatidylethanolamine ; PEG: poly(ethyleneglycol); PEG15H: Macrogol 15 hydroxystearate or Polyoxyl 15 Hydroxystearate or SOLUTOL HS® 15 or KOLLIPHOR®
HS15 or PEG-660 stearate; PEG100: polyethylene glycol (100) monostearate; PEG400: polyethylene glycol (400) monostearate; PEG660: polyethylene glycol (660)
monostearate PEG2000: polyethylene glycol (2000) monostearate; PG: propylene glycol; PGPR: polyglycerol polyricinoleate; PVA: Poly(vinyl alcohol); PRECIROL®5
ATO: Glyceryl palmitostearate; PS20: Polysorbate 20 or TWEEN® 20 or polyoxyethylene sorbitan monolaurate; PS60: Polysorbate 60 or TWEEN® 60 or poly-
oxyethylene sorbitan monostearate; PS80: Polysorbate 80 or TWEEN® 80 or polyoxyethylene sorbitan monooleate; SA: Stearic acid or octadecanoic acid or n-
Octadecanoic acid; SH-SY5Y cells or SK-N-SH cells: human neuroblastoma cells; SPC: soybean phosphatidylcholine; TG (16:0): 1,2,3-trihexadecanoyl-sn-glycerol or
Tripalmitin or 1,2,3-trihexadecanoyl-glycerol; TG (18:1): Triolein or glyceryl trioleate or 1,2,3-tri-oleoyl-glycerol or 1,2,3-tri-(9Z-octadecenoyl)-glycerol or Glyceryl
trioleate; TPGS: D-α-tocopheryl polyethylene glycol 1000 succinate; TRANSCUTOL®: Diethylene glycol monoethyl ether or Ethoxydiglycol or Carbitol; Vit E: Vitamin
E or Tocopherol; WITEPSOL ®H15: composed by a blend of hydrogenated coco-glycerides (C12–C18).
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methods need low energy as the fabrication is dependent on the oil’s
and surfactant’s physicochemical characteristics and on the modulation
of interfacial phase transitions. On the other hand, as the name implies,
uses devices that take advantage of a very high energy to produce na-
noemulsions. These method includes the high-pressure homogeniza-
tion, which is the most common method used for nanoemulsions pro-
duction. (Date et al., 2010).
6.5.1. Self-Nanoemulsifying drug delivery system (SNEDDS)
SNEDDS are deﬁned as thermodynamically unstable isotropic mix-
tures constituted by oil, surfactants, and drug, and when these SNEDDS
components are introduced into aqueous environment below moderate
agitation, they promptly and spontaneously originate O/W nanoemul-
sions (Fig. 4) (Date et al., 2010). These systems have the ability to
emulsify nanodroplets of oil in water due to surfactants that are added
to the oily phase (a surfactant and sometimes also a co-surfactant is
added to improve the drug entrapment and simplify nanoemulsiﬁca-
tion). The process of self-emulsifying depends on the surfactant’s and
oil’s nature, as well as on the surfactant’s concentration and the tem-
perature in which the process occurs [1]. Also, in human body, the
digestive motility of the gastrointestinal tract (GIT) provides the me-
chanical strength neededgett to help the nanoemulsion formation (Date
et al., 2010).
In direct contrast with the current nanoemulsions, SNEDDS present
many advantages such as: i) drug selective targeting due to GIT speciﬁc
absorption; ii) controlled delivery proﬁles; iii) improved stability pro-
ﬁles even in long-term storage and iv) ability to ﬁll SNEDDs into unit
dosage forms (Date et al., 2010; Pujara, 2012).
6.5.2. Self-Double-Emulsifying drug delivery system (SDEDDS)
SDEDDS are polydispersed systems that promisingly emerged in
order to increase the oral bioavailability of numerous drugs that have
low water solubility, allowing the transport of compounds in droplets of
oil, during its route through the GIT. In other words, these type of
emulsions holds great utility in prolonged delivery of drugs once the
drug located in most inner phase is forced to partition itself over nu-
merous phases prior to release at the site of action (Chourasia and
Khutle, 2015; Pujara, 2012).
SDEDDS arose from the SNEDDS concept with the purpose of in-
creasing drug bioavailability with low permeability and high solubility
(Chourasia and Khutle, 2015). To accomplish this intent, SDEDDS are
comprised by formulated mixtures of hydrophilic surfactants and
water-in-oil emulsions, that resembling SNEEDS, are able to sponta-
neously emulsify in the mixed aqueous gastrointestinal environment
giving rise to water-in-oil-in-water emulsions (W/O/W SDEDDS –
Fig. 4) (Qi et al., 2011). Non-aqueous SDEDDS can be also produced by
formulating mixtures of oil-in-oil and lipophilic stabilizers, that when
mixed with hydrophilic surfactants can spontaneously emulsify in oil-
in-oil-in-water emulsions (O/O/W SDEDDS Fig. 4) (Hu et al., 2016).
7. Lipid nanocarriers containing natural compounds as delivery
systems treating age related neurodegenerative diseases
Encapsulating natural compounds in lipid NC conjugates the bene-
ﬁcial neuroprotective eﬀects of the phytochemicals (described in
Table 1) with the improvement of their pharmacokinetic proﬁle pro-
vided by the NC. Furthermore, as previously stated, lipid NC can be
made to imitate LDL and be able to interact with LDL receptors, which
triggers uptake by the brain’s endothelial cells. Table 3 depicts an
overview of reported lipid NC containing natural compounds used for
their neuroprotective eﬀects and/or prospective treatment of ARND
and the following subsections summarize the most relevant achieve-
ments of these studies.
7.1. Improvements in bioavailability and pharmacokinetic proﬁle of natural
compounds
Poor bioavailability is one of major hurdles in therapeutic devel-
opment, particularly in the area of CNS mainly due to natural com-
pounds’ poor solubility and membrane permeability that is limited,
metabolism of the gut-wall, and transporter-mediated intestinal secre-
tion. Furthermore, natural compounds present poor pharmacokinetic
proﬁles and a short half-life being rapidly and extensively metabolized
and excreted. This implies that large doses of natural compounds are
required to reach therapeutically eﬀective plasma concentrations
(Huang et al., 2011; Wei et al., 2014) (Blasina et al., 2015). Therefore,
enhancing the natural compounds bioavailability and pharmacokinetic
proﬁle is urgently needed and lipid NC address this problem.
Liposomes have improved quercetin, baicalin, curcumin and sal-
vianolic acid B bioavailability in animal models (Blasina et al., 2015;
Meng et al., 2015; Wei et al., 2014). Quercetin plasma levels measured
after the administration of liposomal were 1.2 ± 0.8mg/mL at half an
hour and 1.1 ± 0.7mg/mL at one hour in comparison with free
quercetin for which the samples of basal plasma showed no natural
compound content (Blasina et al., 2015) Six hours after the adminis-
tration of the liposomal formulation, quercetin was still available
(Blasina et al., 2015). Regarding baicalin, liposomes signiﬁcantly in-
creased its content in the liver to 5.59-fold, the spleen to 2.33-fold, and
the lung to 1.25-fold respectively (Wei et al., 2014). Furthermore, the
curcumin concentration in the blood after curcumin-loaded liposomes
are intravenously administered at 4 h was 13.03 ng/mL, while the free
curcumin concentration in the blood reduced drastically in the ﬁrst 2 h
and by 4 h was undetectable. (Meng et al., 2015). Moreover, compared
with free curcumin solution, curcumin-loaded liposomes showed 2.55
folds higher area-under-curve (AUC) and a prolonged stay in a body
had a multiple of 4.49 greater mean residence time (MRT) and a 1.81
times lesser chances of being eliminated from the body. (Meng et al.,
2015). Salvianolic acid B-loaded PEGylated liposomes also displayed a
concentration of plasma that was over the 4-fold compared to unloaded
compound and consequently the in vivo eﬃcacy of the liposomal loaded
compound was also increased (Isacchi et al., 2011).
Ethosomes, were also successful increasing (± ) catechin plasma
level in comparison to an equivalent aqueous solution. Consequently,
ethosomes delivered (± ) catechin to diﬀerent regions of the brain
(thalamus, hippocampus, and cortex, striatum) with comparatively
high concentrations in relation to those that come from the aqueous
solution (Huang et al., 2011).
Micelles were used to improve curcumin’s bioavailability approxi-
mately 10 to 40-fold in brain tissue and murine plasma (Hagl et al.,
2015).
Nanoemulsions signiﬁcantly increased the bioavailability of schi-
santherin A to 47.3%. Furthermore, intranasal administration of na-
noemulsions increased about 7 and 9-fold the AUC in brain rat tissues
for resveratrol and curcumin, respectively (Nasr, 2016). Pharmacoki-
netic parameters obtained after intranasal and i.v. administration of
thymoquinone mucoadhesive nanoemulsion compared with free thy-
moquinone were signiﬁcantly improved in brain, lungs and plasma.
Additionally, results clearly showed that when administered through
intranasal route the developed nanoemulsion was found to be very ef-
fective in enhancing brain thymoquinone bioavailability (Ahmad et al.,
2016).
Finally, lipid nanoparticles, such as SLN and NLC were also used to
improve bioavailability of natural compounds. NLC doubled the oral
bioavailability of EGCG in animal models, making it more eﬀective,
even at reduced concentrations (Smith et al., 2010). NLC also increased
the plasma level and half-life (t1/2) of baicalein compared to an
equivalent aqueous solution and showed a protective eﬀect of the
natural compound against chemical instability. The eﬃciency of brain
targeting by baicalein was improved greatly by NLC, especially to the
cortex and brain stem (Tsai et al., 2012). Developed SLN and NLC were
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also able to advance quercetin’s relative bioavailability by 3.5-fold and
5.4-fold, respectively in comparison with free compound. The process
of absorption by NLC (at 0.48 h−1) was quicker compared to SLNs
absorption process (at 0.39 h−1) and that of free compound (0.37 h−1).
Furthermore, SLN and NLC managed to delay the quercetin clearance
by 3.5 times and 5.8 times, respectively, which pointed to a signiﬁcant
increase in quercetin biological residence when it is administered en-
capsulated in NC. Plain quercetin was eradicated largely after 6 h
elapsed since administration, while the compound delivered using na-
noparticles was retained in fairly large amounts. The NC were also able
to enhance quercetin’s the brain delivery by a multiple of 5.6 (NLC) and
3.2 (SLN).These ﬁndings demonstrated the superiority of NC (SLN and
NLC), generally and NLC, speciﬁcally to increase quercetin’s that is
poor and increase the period of residence in the body and consequently
increase its brain distribution (Kumar et al., 2016). The bioavailability
of curcumin was also signiﬁcantly increased when it was included in
the SLN and its pharmacokinetic parameters improved (32–155 times)
as well as its pharmacodynamics parameters (3–4 times). The presence
of SLN containing curcumin in brain and plasma pointed to the delivery
of the NC across the BBB and gut wall and as eﬀective. Curcumin de-
livered by these NC into the brain had 30 times more preferential dis-
tribution, which ascertained their promising use in the treatment of
ARND (Kakkar and Kaur, 2011; Kakkar et al., 2013a, b). SLN of palmitic
acid and cholesterol decorated with chitosan were also able to increase
AUC and t1/2 of curcumin and had a higher brain distribution that
unloaded curcumin (Ramalingam and Ko, 2015). Also, using SLN was
possible to increase the t1/2 of luteolin of about 2 h. The clearance and
distribution of luteolin with SLN were substantially reduced by 2.16
fold and 10.57 fold, respectively. Therefore SLN containing luteolin
showed 4.89 times more bioavailability than unloaded luteolin (Dang
et al., 2014). Bioavailability of piperine was also enhanced by en-
capsulation of this natural compound in SLN reaching higher maximum
plasma concentrations (121 ± 6.78 ng/g) and 2 fold AUC compared to
unloaded piperine (51 ± 9.34 ng/g) (Yusuf et al., 2013). Finally, SLNs
prolonged resveratrol release up to 120 h and the lipid formulation
produced an 8-fold increase in oral resveratrol bioavailability in rats.
The t1/2 was found to increase from 2.4 h to 11.5 h when resveratrol
was loaded in SLNs (Pandita et al., 2014).
The reasons pointed for the success of lipid NC improving oral
bioavailability and pharmacokinetic proﬁle of natural compounds are
the small size and composition of the NC (Blasina et al., 2015; Wei
et al., 2014). The reduced size of the NC increases the lipid surface area
and consequently improves: (i) dissolution rate of the natural com-
pounds; (ii) permeability of the natural compounds through biological
membrane (iii) and absorption of the natural compounds in the gas-
trointestinal tract (i.e. bioavailability increase). The NC lipid composi-
tion has also a role on GIT absorption. Lipid NC that mimic the phy-
siological micelles (formed in the intestine) will be taken up from gut to
blood by the phagocytotic Peyer patch M cells and will consequently
improve the absorption of lipophilic ingredients. Another possibility for
the enhanced absorption, is the increased partitioning of natural com-
pounds encapsulated in lipid NC from the GIT to the gut wall, in
comparison with the free compounds, which eventually results in pas-
sive permeation that is enhanced across this biomembrane.
Speciﬁc elements of lipid NC composition were also pointed out as
important in enhancing absorption of natural compounds. This is the
case of long-chain triglycerides and surfactants (such as polysorbate 80,
lecithin or other phospholipids) that promote the lymphatic absorption
of the actives from GIT. This prevents the ﬁrst-pass metabolism and
may lead to permeation improvements of natural compounds via the GI
membrane, resulting in an increased oral absorption (Sa et al., 2015a;
Wei et al., 2014). The bioadhesive character of these components can
also rise the NC’s and GI membrane’s aﬃnity between them. The re-
sultant longer residence time at the absorption site would assist in in-
creasing the natural compounds uptake. The same role of increasing the
retention and penetration of SLNs in the GI tract was achieved by
decorating the surface of SLNs with N-trimethyl chitosan (Ramalingam
and Ko, 2015, 2016).
Moreover, the role of polysorbate 80 (or TWEEN® 80) in absorption
cannot be ignored. The P-glycoprotein eﬄux system is also fairly in-
hibited by polysorbate 80 leading to improved delivery of natural
compounds. The same role had the surfactant Brij 78 and D-α-toco-
pheryl polyethylene glycol 1000 succinate (TGPS) used to decorate
curcumin-loaded SLNs and to inhibit the P-glycoprotein eﬄux pump
with a resultant permeability enhancement of 1.3 times and 1.4 times
greater than conventional SLNs in the jejunum (Ji et al., 2016).
Furthermore polysorbate 80 can also give raise to steric hindrance
in lipid NC providing protection and resistance to NC elimination from
the blood circulation (Hagl et al., 2015; Huang et al., 2011; Wei et al.,
2014). In addition, cholesterol in lipid NC is likely to supply better
resistance against pancreatic lipase thereby can be used to guard the
natural compound from an intestinal medium attack (Blasina et al.,
2015; Huang et al., 2011). Gelucires® (a lipid-based excipients family
made up of a mixture of glycerides and PEGylated fatty acid esters) and
vitamin E are also described as playing important roles in improving
lipid NC resistance and enhancing the pharmacokinetics and brain
transport (Tsai et al., 2012).
As a ﬁnal point, the lipid composition is also important to assure the
integrated natural compound’s sustained release in a system of delivery
which is a crucial property that often correlates with improved eﬃcacy
and pharmacokinetics (Huang et al., 2011; Tsai et al., 2012).
7.2. Administration routes to deliver natural compounds to brain
The administration routes used to deliver lipid NC containing nat-
ural compounds can be classiﬁed into two major categories: local NC
delivery and systemic administration. Local NC delivery have the ad-
vantage of providing eﬀective therapeutic concentrations of bioactives
in the brain guaranteeing total bioavailability of the bioactive com-
pound and avoiding all the physiological barriers that bioactives would
encounter, including the BBB. However, local NC delivery requires
surgeries or invasive methods to place NC in the brain. Moreover ad-
ditional surgeries may be necessary if the treatment requires multiple
doses. Examples of local NC delivery include intracerebroventricular
administration (i.c.v) or implantation by stereotaxic administration (a
minimally invasive form of surgical intervention which makes use of a
three-dimensional coordinate system to place NC). Due to the technical
requirements of this type of local administration route only few studies
have used it (Lazar et al., 2013; Vedagiri and Thangarajan, 2016).
The majority of lipid based NC loaded with bioactives are ad-
ministered to CNS systemically, most likely via intravenous (i.v.) in-
jection because of the ease of application and avoidance of the ﬁrst pass
eﬀect (Ahmad et al., 2017, 2016; Blasina et al., 2015; Dhawan et al.,
2011; Meng et al., 2015; Rivera et al., 2008; Sarkar and Das, 2006; Tsai
et al., 2012; Ye et al., 2014). Other systemic administrations include:
oral administration (Dang et al., 2014; Hagl et al., 2015; Huang et al.,
2011; Kakkar and Kaur, 2011; Kakkar et al., 2013a, b; Kumar et al.,
2016); intraperitoneal administration (i.p) (Galho et al., 2016; Isacchi
et al., 2011; Puglia et al., 2012; Wang et al., 2015; Yan et al., 2014;
Yusuf et al., 2013; Zhao et al., 2011) and transdermal administration
(Hu et al., 2016; Shi et al., 2012).
Intranasal administration has been investigated recently as an al-
ternative to i.v. administration as it is an opportunity to bypass BBB by
transferring the NC from the olfactory mucosa directly to the CNS
through the olfactory pathway. Therefore this route gives direct access
of NC loaded with bioactives to the brain and oﬀers a new means for the
long-term non-invasive management of chronic neurological disorders
and diseases such as Alzheimer's disease. The beneﬁts that accrue to
nasal administration as opposed to oral route are higher bioavailability
because of lack of ﬁrst pass hepatic metabolism and subsequent rapid
absorption that result in a shorter period to the start of the eﬀect
(Pardeshi and Belgamwar, 2013). In this context, nasal administration
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provides easy brain penetration and a shorter distance to the brain
target to NC containing natural bioactives (Ahmad et al., 2017; Nasr,
2016; Sood et al., 2014; Tong-un et al., 2010).
7.3. Stealth, targeting and triggering strategies to deliver natural compounds
to brain
7.3.1. Stealth strategies
In order to prepare long circulating NC, a PEGylation (PEG) coating
is needed to give stealth properties to avoid recognition of the NC by
the RES system and also to serve BBB targeting ligands that are used in
active targeting strategies as an anchor point. PEGylation is a strategy
widely used in nanotherapy and ARND nanotherapy is no exception, as
additionally it has been documented that PEG coated NC may have
increased aﬃnity for the BBB endothelial cells in a brain that is normal
(Brasnjevic et al., 2009). Therefore, many authors have used PEG as a
stealth strategy in lipid NC containing natural compounds for brain
delivery (Isacchi et al., 2011; Meng et al., 2015; Mourtas et al., 2011,
2014; Phachonpai et al., 2010; Sood et al., 2014; Tong-un et al., 2010;
Yan et al., 2014).
This was the case of liposomes containing salvianolic acid, where
the PEGylation has been associated with an increase of the natural
compound plasmatic concentration over 4-fold compared to other for-
mulations. In this study the inclusion of PEG in the liposomes surface
may have modiﬁed the salvianolic acid’s pharmacokinetic proﬁle, its
plasma protein binding and/or its metabolism (Isacchi et al., 2011).
7.3.2. Active targeting strategies
Surface functionalization with speciﬁc ligands is an active targeting
strategy that directs lipid based NC to some receptors that are over-
expressed in brain capillary endothelial cells. One literature example of
this strategy was the functionalization of NLC surface with lactoferrin
(Lf) for curcumin brain delivery (Meng et al., 2015). Lf is a naturally
occurring cationic glycoprotein that is iron binding and is capable of
being moved across BBB through lactoferrin receptors (LfR). Moreover,
an increase of LfR in the brain capillary endothelial cells has been found
in PD and AD (Meng et al., 2015). In this context, curcumin loaded Lf-
NLC with Lf at high levels had higher uptakes (1.39 times higher) by the
brain capillary endothelial cells than naked NLC (Meng et al., 2015).
Additionally, FRET studies showed that curcumin was still inside NLC
after uptake by brain capillary endothelial cells, showing the carrier’s
stability travelled across the BBB. Studies of Ex vivo imaging also con-
ﬁrmed that Lf-NLC could permeate BBB eﬀectively and accumulate
preferentially in the brain (Meng et al., 2015). In agreement with the
higher brain concentration of Lf-NLC, the Lf-NLC’s superior eﬃcacy in
the control of AD associated damage was conﬁrmed through histo-
pathological evaluation (Meng et al., 2015).
Another active targeting strategy used for the delivery of curcumine
across BBB was the functionalization of liposomal surface with mono-
clonal antibodies anti-transferrin receptor (OX26 an anti-TfR mAb).
This strategy was chosen because TfR are highly expressed in BBB en-
dothelial cells. Besides brain targeting capability, these liposomal NC
have also demonstrated capacity to target Aβ deposits in the brain
through curcumin-derivative molecules presence on their surface.
Therefore, these multifunctional formulations could be used for ther-
anostic (therapy by curcumin neuroprotective eﬀect and diagnostic by
curcumin labelling of Aβ deposits) purposes (Mourtas et al., 2014). The
same strategy of targeting TfR with OX-26 antibody was used in SLN
loaded with resveratrol from grape skin and grape seed extracts
(Loureiro et al., 2017). OX-26 functionalization increased uptake of
resveratrol loaded SLN by BBB cell model and transcytosis across the
BBB cell model when compared with SLN functionalized with another
antibody (LB 509) or with non-functionalized SLN (Loureiro et al.,
2017).
Due to mannose receptors being present in the brain, mannosylated
liposomes containing quercetin were also used to attempt carrying out
drug delivery that was site speciﬁc to cerebral tissue (Sarkar and Das,
2006). The authors of this formulation concluded that the administra-
tion of non-encapsulated quercetin in rats had no signiﬁcant anti-
oxidant eﬀect and thus no signiﬁcant brain protection in aged or young
rat brain (Sarkar and Das, 2006). Contrastingly, a single injection of the
same amount of quercetin encapsulated in mannose-grafted liposomes
decreased and got the oxidation products to near normal levels. This
indicated that, treatment of quercetin encapsulated in mannosylated
liposomes conferred protection against oxidation and cerebral edema
(Sarkar and Das, 2006).
Another active targeting strategy widely used for brain delivery of
natural compounds was coating the lipid NC surface with polysorbate
(Wei et al., 2014). Polysorbate has been described as able to facilitate
the functionalization of NC surface with LDL receptor ligands (ApoE
and/or serum ApoB). Consequently, the NC are targeted towards the
LDL receptor (low-density lipoprotein receptors (LDLR)) on the capil-
lary endothelial cells of the brain and are internalized, mimicking
natural lipoproteins’ transcytosis (Georgieva et al., 2014). Using the
same strategy, ApoE functionalized SLN improved resveratrol perme-
ability (1.8-fold higher) into human brain capillary endothelial cells
when compared to non-functionalized NC (Neves et al., 2016).
Furthermore, polysorbate as well as other detergents like sodium
dodecyl sulfate (SDS), or other solvents like ethanol and DMSO can rise
BBB vascular endothelium’s permeability. The BBB permeability en-
hancement is possibly due to the detergent’s/solvent’s destabilizing
eﬀect of a membrane leading to BBB disruption (Brasnjevic et al.,
2009). The same BBB permeability enhancement strategy is used in
lipid NC containing high quantities of ethanol (ethosomes), for brain
delivery of natural compounds (Huang et al., 2011; Shi et al., 2012).
7.3.3. Passive targeting strategies
In several neurodegenerative and brain injury diseases non-speciﬁc
pathologic changes like fenestrations formation may occur. It has been
further reported that in the BBB, the fenestrations formation that are
100 nm in size can allow for molecular aggregates like liposomes to
pass, which ordinarily cannot reach the brain. It was also reported that
to cross the BBB, the lipophilic vesicles may use transcellular diﬀusion
(Kakkar and Kaur, 2011). In addition, the overexpression of the LDLR in
brain capillary endothelial cells gives the beneﬁt of targeting the brain
for lipid based NC. Based on these assumptions, lipid NC with a con-
trolled size are reported as able to reach brain tissues even without
additional surface functionalization. These passive targeting strategies
have indeed been observed for the uptake of SLN containing curcumin
by brain endothelial cells (Kakkar et al., 2013b). SLN are reported as
being taken up readily by the brain because of their lipid nature and
their nanometer size which facilitates their passage across the BBB, thus
being suitable for passively target the brain (Sachdeva et al., 2015).
Additional passive targeting strategies include the positively
charged NC that can make use of the AMT mechanism of adsorption to
the negatively charged surface of brain endothelial cells and transport
across BBB. Furthermore, NC covered by positively charged mu-
coadhesive polymers, prolong the contact time for bioactives in the
nasal cavity whereby it provides an opportunity for tight junctions to
open hence increasing permeation and sustained bioactive delivery to
brain. Chitosan is an example of positively charged mucoadhesive
polymer used as coating for nanoemulsions containing curcumin, sa-
franal or thymoquinone for nasal administration (Ahmad et al., 2017,
2016; Sood et al., 2014). Besides mucoadhesive polymers, surfactants
and other formulation components like cholesterol also favor the
opening of tight epithelial junction in nasal membrane, increasing
bioactives’ penetration. Accordingly, nasal administration of liposomes
containing quercetin has been developed as a possible protection
strategy against neurodegeneration and these systems have shown
beneﬁcial eﬀects with very low dose of natural compound (Sood et al.,
2014). The same strategy of nasal administration and BBB bypass was
used by the combination of CREMOPHOR® RH 40 (known for its
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enhancement of cell membrane ﬂuidity and thus used as permeation
enhancer) and hyaluronic acid (reported to improve the mucosal ab-
sorption of drugs) to increase the nose to brain transport of curcumin
and resveratrol through the olfactory pathway (Nasr, 2016). This
composition was reported as able to reduce mucociliary clearance and
increase the persistence of the formulation containing natural com-
pounds in the nasal cavity without causing any tissue damage or epi-
thelial and ciliotoxicity (Nasr, 2016).
7.3.4. Triggering strategies
To attain NC controlled release, these can be modiﬁed in the
structure with triggering strategies such as pH response, photo re-
sponse, bioenzymatic response, and thermal response. A recent study,
using photo responsive liposomes loaded with sasanquasaponin has
used this triggering strategy to control the natural compound release by
infrared light that has deep penetration and low tissue damage. The
photo responsive liposome was composed of a mixture of lecithin and a
photosensitive agent (phaeophorbide) that could be activated by a laser
light of 670 nm. Upon excitation, this photosensitive agent is a singlet
oxygen or oxygen radicals’ generator that damage the phosphodiester
bonds in the NC lecithin, this way releasing sasanquasaponin.
Additionally, to the controlled release of the natural compound, the
advantages of this formulation are the fact that the irradiation and re-
lease could be done in nasal cavity, provoking little harm (Ye et al.,
2014).
7.4. Biodegradation/bioelimination of lipid nanocarriers from the brain
The biological fate of NC is still a research topic that requires more
attention. Some NC are not readily eliminated by clearance mechan-
isms, and can cause brain bioaccumulation prompting additional cy-
totoxicity (Medina et al., 2007). Although several types of NC composed
by inorganic nanomaterials, were more thoroughly studied for their
potential toxicity (Costa et al., 2016; Hu and Gao, 2010), fewer studies
were concerned with the lipid NC, as these are biodegradable, and for
that reason considered to not accumulate in the body and regarded as
possibly risk-free (Medina et al., 2007; Qi et al., 2017). Other argu-
ments that hinder further investigation of the biological fate of lipid NC
are based, for instance, in the fact that lipid-based parenteral nutrition,
has been clinically used since the early 1960s. Furthermore all the lipid
components of lipid NC for human use are generally recognized as safe
(GRAS) (Blasi et al., 2007). Nevertheless, the eﬀects of NC, even of the
ones considered biodegradable, on BBB dysfunction and associated
consequences are still not well identiﬁed. Thus novel studies dealing
with the neurotoxic eﬀects of several classes of NC on the CNS function
are compulsory. This is even more important considering that the
speciﬁc mechanisms through which the NC or its degradation products
may exert their toxic eﬀects remain largely unknown and no guidelines
are presently available to quantify these eﬀects (Hu and Gao, 2010;
Sharma, 2007).
From a general standpoint it is true that lipid NC can be considered
as having higher acceptability than other NC made of polymeric or
inorganic materials. However it is also important to emphasize that
besides the tolerability of the lipid constituents, other components are
often used in the formulation of lipid NC. For instance, SLN and NLC
include surfactants in their composition, and its tolerability and inﬂu-
ence in biodegradation must be considered as well (Blasi et al., 2007).
For instance, the biodegradation has shown to be slower when trigly-
cerides with long chain fatty acids and/or sterically hindering surfac-
tants like Poloxamer 407 or Poloxamine 908 were part of SLN com-
position. Contrastingly, a faster degradation was achieved when the
lipid nanoparticles composition includes short chain fatty acid trigly-
cerides and/or degradation promoting surfactants like bile salts (e.g.
cholic acid sodium salt) (Olbrich et al., 2002). Furthermore, it has also
to be considered the inﬂuence of particle size on biodegradation rate as
this has shown to be diﬀerent for certain surfactants (Olbrich et al.,
2002). All in all it may be assumed that several factors aﬀect the bio-
degradation of lipid based NC whose rate depends on several factors
such as the lipid composition, particle size, surface decoration, presence
of lipases (body enzymes capable of lipolysis) (Qi et al., 2017).
Additionally, the degradation products resultant from lipolysis
should not be seen as innocuous risk-free metabolites, especially con-
sidering that brain is the organ with highest concentration of lipids next
to adipose tissue, demonstrating that lipids metabolism have important
role in the CNS (Adibhatla and Hatcher, 2008). Important proofs of the
lipids role in brain were given by more and more studies that demon-
strated that neurons located at speciﬁc regions of the brain (e.g. hy-
pothalamus, hippocampus or striatum) are sensitive to free fatty acids
which presence are able of changing their nervous activity (Cruciani-
Guglielmacci and Magnan, 2017). Therefore, it is not diﬃcult to assume
that a local hydrolysis of lipid NC may also participate to brain lipid
sensing due to the free fatty acids produced that could then act in the
sensitive neurons. Furthermore, phospholipids can also result from
degradation of lipid NC and exert their role as precursors of in-
ﬂammation mediators such as arachidonic acid a substrate of phos-
pholipase A2 (Adibhatla and Hatcher, 2008). Moreover, the products of
degradation of lipid NC, free fatty acids and phospholipids, can both
suﬀer another pathway of degradation: lipid oxidation that occurs in
astrocytes, resulting in elevated ketone levels in the brain (Bruce et al.,
2017; Foradada et al., 2000). The brain is especially vulnerable to this
oxidation products as it has a high oxygen consumption rate and re-
duced antioxidant enzymes (Hu and Gao, 2010), and hence the oxida-
tive stress products resultant from lipid NC degradation can lead to
inﬂammation and neuron injury.
The lipid role in brain and in neurodegenerative diseases is also
highlighted by the fact that lipid rafts (lipid domains enriched in cho-
lesterol, sphingolipids and saturated fatty acids) disruption is an early
marker for diagnosis of the disease (Wang and Eckel, 2014). It has been
stated that lipid rafts are aﬀected by lipoproteins metabolism which
may be linked to atherosclerosis or neurodegenerative diseases (Wang
and Eckel, 2014). Considering that lipid NC use the same pathway (e.g.
LDL receptors) as lipoproteins to be transported to the brain (Alam
et al., 2010) it is tempting to suggest that, like lipoproteins, lipid NC
degradation products may also modulate lipid raft signal platforms.
For all the exposed, lipid NC biodegradation and lipid byproducts of
such degradation should be carefully analyzed as may be involved in
lipid rafts impairment, inﬂammation processes or neuron modulation.
Besides biodegradability studies, the lipid composition should not
provide a guarantee per se of biocompatibility, and their use in brain
diseases should be accompanied with more detailed studies. For ex-
ample, concerning liposomes, several studies provide evidences of hy-
persensitivity reactions as these NC can activate complement system
(CS), and larger liposomes (200 nm or above) appeared to be stronger
CS activators than their smaller counterpart of identical lipid compo-
sition and equivalent total surface area (Gregori et al., 2015). Since all
the studies refer the CS activation in blood, further studies on liposomal
biocompatibility should be conducted in CNS to provide further
awareness on the threats associated with this promising targeting sys-
tems.
8. Conclusions and future perspectives
Considering the overlapping pathways thought to be triggered in
the onset of ARND, one proposed option is that treatments can be
founded on natural compounds that ally their safe use to their multiple
beneﬁcial neuroprotective eﬀects though quantitatively small when
alone, are synergistic, especially over the time duration. The potential
of nanotechnology makes it possible for it to be utilized in facilitating
delivery of natural compounds across the BBB, to help the neurons
functional regeneration and improve the neuroprotective strategies.
The encapsulation of natural compounds in NC protects them from
degradation and improves their half-life in circulation.
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Functionalization with ligands that target proper receptors on the BBB
can concentrate NC loaded with natural compounds within BBB cells or
promote their entrance in the brain. Thus, nanoencapsulation devel-
opment strategies to improve the bioavailability and increase the ab-
sorption of natural compounds is of uttermost signiﬁcance as an ARND
therapeutic or prophylactic approach. Generally, the studies analyzed
in this discussion showed that lipid NC are capable of enhancing oral
bioavailability and/or pharmacokinetic proﬁle of natural compounds
being also capable of delivering these compounds to brain.
Alternatively, intranasal injections facilitate the direct delivery of nat-
ural compounds into the brain bypassing the BBB.
However, many issues remain to be considered before we can
beneﬁt from suitable nanotechnology-based delivery systems that could
lead to improved ARND therapeutic and prophylactic outcomes. First of
all, most studies lack of a thorough characterization of the lipid NC
developed, or provide an incomplete or non-systematic methodology of
formulation development. Indeed, formulation development is often
made in a “trial and error” based method and most of the studies do not
consider the inﬂuence of NC composition in: (i) natural compounds
encapsulation and loading eﬃciency; (ii) NC size, surface charge po-
tential; (iii) ability of NC to completely release the entrapped bioac-
tives; and ultimately (iv) NC eﬃciency to deliver natural compounds to
brain where their eﬀects are evaluated. For instance, despite the re-
cognized beneﬁt of a positively charged surface to be able to cross BBB
using AMT mechanisms, the majority of the NC developed displayed a
negatively charged surface. Moreover, despite most authors refer the
size of the NC as an important requirement to cross BBB, this is not a
concern for many of the formulations developed.
Besides this, caution is needed because a successful transportation
of a lipid NC that has natural compounds across in vitro BBB simulated
model is not predictive of its therapeutic eﬀect fully, due to the fact that
after the bioactive penetrates across the BBB it is equally essential to
analyze if its biological activity is retained or not. On the other hand, In
vivo models provide evidences on the improvement of natural com-
pounds beneﬁts upon its encapsulation in lipid NC, however studies
were mainly examined by acute or short-term animal models after short
duration neurotoxic insults. This seems an inappropriate timing as the
long latency period of ARND adds another dimension in its complexity
wherein the principal mechanisms change with the time course and
progression of the diseases. Therefore, to make most out of the potential
of lipid NC as delivery systems for natural compounds across BBB,
longer term in vivo clinical trials and pharmacokinetic studies are re-
quired to aﬃrm the capacity of these NC to enhance the eﬃcacy and
bioavailability of natural compounds.
Another issue that requires consideration is the safety of NC that is
developed. The toxicity and safety features of NC are signiﬁcant con-
siderations that require seriousness, need to be understood well and
resolved before the implementation of these formulations for clinical
use for ARND treatment. In fact, despite being made of biocompatible
constituents, the biological fate of lipid NC can be determined not only
by their composition but also by their shape, size that ultimately de-
termine their biological interactions. Thus, long term toxicity and
pharmacodynamic implications of the oﬀ-target actions of these lipid
NC should be studied as it can show diﬀerential eﬀects on ARND pa-
thology.
Looking back at so many open issues make us think - are lipid NC
loaded with natural compounds potential new therapies for ARND? Yes,
deﬁnitely. Classical therapeutic approaches for AD and other ARND are
limited to a single target and have produced disappointing results in
clinical trials. There is no doubt of the beneﬁcial role of natural com-
pounds in several targets of ARND pathology. The improvement of
safety data knowledge and the optimization of nanoencapsulated for-
mulations of natural compounds are the succeeding mandatory steps, as
well as ﬁnding speciﬁc targeting strategies of diseased areas in the brain
and reducing adverse eﬀects to healthy cells. This review and ob-
servations of this critical perspective oﬀer several key points that can
help identify potentially problematic research approaches and/or in-
terpretation of outcomes in publications, as increasing our compre-
hension about these diseases challenges will contribute to the devel-
opment of novel potential therapeutic strategies.
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